An ASX listed medical device company with big upside. OSP's FDA approved DyeVert device reduces the amount of contrast iodine injected into patients undergoing common heart and peripheral vascular procedures such as angioplasty and stenting. The company has a market cap of USD60m and is most likely fully funded through to break-even. A pilot study has proven the commercialisation opportunity. We think OSP's new sales force will succeed in generating rapid growth - our conservative estimate of the success of the sales strategy sees earnings at USD25m within 5 years. We are backing the CEO who is a veteran salesman with an established track record of commercialising new medical devices.